Key Takeaways
- Phase II is primarily for market learning; Phase III converts learning into operational decisions.
- First-launch companies need longer lead time because capabilities are often built from zero.
- Roadmaps should sequence leadership, access, organization and governance—not only promotional tactics.
- Use illustrative timing; actual sequencing depends on therapy, indication and market.
Emerging biotechnology companies benefit from a shared commercialization roadmap that connects clinical progress to commercial readiness.
This is not a universal calendar. It is a way to organize decisions so capabilities are not discovered eighteen months before launch when they require three years to build. For a visual stage view, see the 36-month launch roadmap.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
